Global Recombinant Vaccines Market

Recombinant Vaccines Comprehensive Study by Type (Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines, Vector Recombinant Vaccines), Application (Recombinant Human Vaccines, Animal Recombinant Vaccines), Distribution Channel (Hospitals, Private Clinics & Dispensaries, Retail Pharmacies, Others) Players and Region - Global Market Outlook to 2026

Recombinant Vaccines Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 6.1%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Recombinant vaccines are derived from killed vaccines. Their synthesis is non-toxic in nature. They contain highly immunogenic microbial antigens and are made with the help of recombinant DNA technology. Worth noting that the antigen component of subunit vaccines is covalently linked to a carrier, mostly a protein. Recombinant vaccines are projected to gain popularity as they provide great benefits for the patient, reduced side effect profiles, and reduced costs associated with therapeutic intervention as the hospital expenditure is reduced using recombinant vaccines.
According to AMA, the market for Recombinant Vaccines is expected to register a CAGR of 6.1% during the forecast period to 2026. This growth is primarily driven by High Prevalence of Infectious Diseases and Rising Focus on Immunization Programs.

Globally, a noticeable market trend is evident Growing Government Support for Recombinant Vaccines . The Pharmaceuticals sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Merck & Co., Inc (United States), Green Cross Corporation (South Korea), Pfizer Inc. (United States), Bayer AG (Germany), Sanofi S A. (France), Protein Science Corporation (United States), GlaxoSmithKline Plc. (United Kingdom), Novartis AG (Switzerland) and Bharat Biotech (India) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Market Drivers
  • High Prevalence of Infectious Diseases
  • Rising Focus on Immunization Programs

Market Trend
  • Growing Government Support for Recombinant Vaccines
  • Increasing Company Initiatives to Enhance Vaccine R&D
  • The Increasing Awareness about Recombinant Vaccines

Restraints
  • High Cost associated with Vaccine Development

Opportunities
High Growth From Emerging Markets and Growing demand for Optimized & Sustainable Healthcare
Challenges
Inadequate Access to Vaccines

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Recombinant Vaccines Study Sheds Light on
— The Recombinant Vaccines Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Recombinant Vaccines industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Recombinant Vaccines industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Subunit Recombinant Vaccines
  • Attenuated Recombinant Vaccines
  • Vector Recombinant Vaccines
By Application
  • Recombinant Human Vaccines
  • Animal Recombinant Vaccines
By Distribution Channel
  • Hospitals
  • Private Clinics & Dispensaries
  • Retail Pharmacies
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Prevalence of Infectious Diseases
      • 3.2.2. Rising Focus on Immunization Programs
    • 3.3. Market Challenges
      • 3.3.1. Inadequate Access to Vaccines
    • 3.4. Market Trends
      • 3.4.1. Growing Government Support for Recombinant Vaccines
      • 3.4.2. Increasing Company Initiatives to Enhance Vaccine R&D
      • 3.4.3. The Increasing Awareness about Recombinant Vaccines
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Recombinant Vaccines, by Type, Application, Distribution Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Recombinant Vaccines (Value)
      • 5.2.1. Global Recombinant Vaccines by: Type (Value)
        • 5.2.1.1. Subunit Recombinant Vaccines
        • 5.2.1.2. Attenuated Recombinant Vaccines
        • 5.2.1.3. Vector Recombinant Vaccines
      • 5.2.2. Global Recombinant Vaccines by: Application (Value)
        • 5.2.2.1. Recombinant Human Vaccines
        • 5.2.2.2. Animal Recombinant Vaccines
      • 5.2.3. Global Recombinant Vaccines by: Distribution Channel (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Private Clinics & Dispensaries
        • 5.2.3.3. Retail Pharmacies
        • 5.2.3.4. Others
      • 5.2.4. Global Recombinant Vaccines Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Recombinant Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck & Co., Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Green Cross Corporation (South Korea)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bayer AG (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanofi S A. (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Protein Science Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GlaxoSmithKline Plc. (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis AG (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bharat Biotech (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Recombinant Vaccines Sale, by Type, Application, Distribution Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Recombinant Vaccines (Value)
      • 7.2.1. Global Recombinant Vaccines by: Type (Value)
        • 7.2.1.1. Subunit Recombinant Vaccines
        • 7.2.1.2. Attenuated Recombinant Vaccines
        • 7.2.1.3. Vector Recombinant Vaccines
      • 7.2.2. Global Recombinant Vaccines by: Application (Value)
        • 7.2.2.1. Recombinant Human Vaccines
        • 7.2.2.2. Animal Recombinant Vaccines
      • 7.2.3. Global Recombinant Vaccines by: Distribution Channel (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Private Clinics & Dispensaries
        • 7.2.3.3. Retail Pharmacies
        • 7.2.3.4. Others
      • 7.2.4. Global Recombinant Vaccines Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Recombinant Vaccines: by Type(USD Million)
  • Table 2. Recombinant Vaccines Subunit Recombinant Vaccines , by Region USD Million (2015-2020)
  • Table 3. Recombinant Vaccines Attenuated Recombinant Vaccines , by Region USD Million (2015-2020)
  • Table 4. Recombinant Vaccines Vector Recombinant Vaccines , by Region USD Million (2015-2020)
  • Table 5. Recombinant Vaccines: by Application(USD Million)
  • Table 6. Recombinant Vaccines Recombinant Human Vaccines , by Region USD Million (2015-2020)
  • Table 7. Recombinant Vaccines Animal Recombinant Vaccines , by Region USD Million (2015-2020)
  • Table 8. Recombinant Vaccines: by Distribution Channel(USD Million)
  • Table 9. Recombinant Vaccines Hospitals , by Region USD Million (2015-2020)
  • Table 10. Recombinant Vaccines Private Clinics & Dispensaries , by Region USD Million (2015-2020)
  • Table 11. Recombinant Vaccines Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 12. Recombinant Vaccines Others , by Region USD Million (2015-2020)
  • Table 13. South America Recombinant Vaccines, by Country USD Million (2015-2020)
  • Table 14. South America Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 15. South America Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 16. South America Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 17. Brazil Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 18. Brazil Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 19. Brazil Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 20. Argentina Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 21. Argentina Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 22. Argentina Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 23. Rest of South America Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 24. Rest of South America Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 25. Rest of South America Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 26. Asia Pacific Recombinant Vaccines, by Country USD Million (2015-2020)
  • Table 27. Asia Pacific Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 28. Asia Pacific Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 29. Asia Pacific Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 30. China Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 31. China Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 32. China Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 33. Japan Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 34. Japan Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 35. Japan Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 36. India Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 37. India Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 38. India Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 39. South Korea Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 40. South Korea Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 41. South Korea Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 42. Taiwan Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 43. Taiwan Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 44. Taiwan Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 45. Australia Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 46. Australia Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 47. Australia Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 51. Europe Recombinant Vaccines, by Country USD Million (2015-2020)
  • Table 52. Europe Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 53. Europe Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 54. Europe Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 55. Germany Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 56. Germany Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 57. Germany Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 58. France Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 59. France Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 60. France Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 61. Italy Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 62. Italy Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 63. Italy Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 64. United Kingdom Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 65. United Kingdom Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 66. United Kingdom Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 67. Netherlands Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 68. Netherlands Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 69. Netherlands Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 70. Rest of Europe Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 71. Rest of Europe Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 72. Rest of Europe Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 73. MEA Recombinant Vaccines, by Country USD Million (2015-2020)
  • Table 74. MEA Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 75. MEA Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 76. MEA Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 77. Middle East Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 78. Middle East Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 79. Middle East Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 80. Africa Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 81. Africa Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 82. Africa Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 83. North America Recombinant Vaccines, by Country USD Million (2015-2020)
  • Table 84. North America Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 85. North America Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 86. North America Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 87. United States Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 88. United States Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 89. United States Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 90. Canada Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 91. Canada Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 92. Canada Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 93. Mexico Recombinant Vaccines, by Type USD Million (2015-2020)
  • Table 94. Mexico Recombinant Vaccines, by Application USD Million (2015-2020)
  • Table 95. Mexico Recombinant Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Recombinant Vaccines: by Type(USD Million)
  • Table 106. Recombinant Vaccines Subunit Recombinant Vaccines , by Region USD Million (2021-2026)
  • Table 107. Recombinant Vaccines Attenuated Recombinant Vaccines , by Region USD Million (2021-2026)
  • Table 108. Recombinant Vaccines Vector Recombinant Vaccines , by Region USD Million (2021-2026)
  • Table 109. Recombinant Vaccines: by Application(USD Million)
  • Table 110. Recombinant Vaccines Recombinant Human Vaccines , by Region USD Million (2021-2026)
  • Table 111. Recombinant Vaccines Animal Recombinant Vaccines , by Region USD Million (2021-2026)
  • Table 112. Recombinant Vaccines: by Distribution Channel(USD Million)
  • Table 113. Recombinant Vaccines Hospitals , by Region USD Million (2021-2026)
  • Table 114. Recombinant Vaccines Private Clinics & Dispensaries , by Region USD Million (2021-2026)
  • Table 115. Recombinant Vaccines Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 116. Recombinant Vaccines Others , by Region USD Million (2021-2026)
  • Table 117. South America Recombinant Vaccines, by Country USD Million (2021-2026)
  • Table 118. South America Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 119. South America Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 120. South America Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 121. Brazil Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 122. Brazil Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 123. Brazil Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 124. Argentina Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 125. Argentina Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 126. Argentina Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 127. Rest of South America Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 128. Rest of South America Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 129. Rest of South America Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 130. Asia Pacific Recombinant Vaccines, by Country USD Million (2021-2026)
  • Table 131. Asia Pacific Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 132. Asia Pacific Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 133. Asia Pacific Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 134. China Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 135. China Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 136. China Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 137. Japan Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 138. Japan Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 139. Japan Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 140. India Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 141. India Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 142. India Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 143. South Korea Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 144. South Korea Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 145. South Korea Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 146. Taiwan Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 147. Taiwan Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 148. Taiwan Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 149. Australia Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 150. Australia Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 151. Australia Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 152. Rest of Asia-Pacific Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 153. Rest of Asia-Pacific Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 154. Rest of Asia-Pacific Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 155. Europe Recombinant Vaccines, by Country USD Million (2021-2026)
  • Table 156. Europe Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 157. Europe Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 158. Europe Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 159. Germany Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 160. Germany Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 161. Germany Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 162. France Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 163. France Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 164. France Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 165. Italy Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 166. Italy Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 167. Italy Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 168. United Kingdom Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 169. United Kingdom Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 170. United Kingdom Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 171. Netherlands Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 172. Netherlands Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 173. Netherlands Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 174. Rest of Europe Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 175. Rest of Europe Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 176. Rest of Europe Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 177. MEA Recombinant Vaccines, by Country USD Million (2021-2026)
  • Table 178. MEA Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 179. MEA Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 180. MEA Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 181. Middle East Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 182. Middle East Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 183. Middle East Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 184. Africa Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 185. Africa Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 186. Africa Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 187. North America Recombinant Vaccines, by Country USD Million (2021-2026)
  • Table 188. North America Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 189. North America Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 190. North America Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 191. United States Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 192. United States Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 193. United States Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 194. Canada Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 195. Canada Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 196. Canada Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 197. Mexico Recombinant Vaccines, by Type USD Million (2021-2026)
  • Table 198. Mexico Recombinant Vaccines, by Application USD Million (2021-2026)
  • Table 199. Mexico Recombinant Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 200. Research Programs/Design for This Report
  • Table 201. Key Data Information from Secondary Sources
  • Table 202. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Recombinant Vaccines: by Type USD Million (2015-2020)
  • Figure 5. Global Recombinant Vaccines: by Application USD Million (2015-2020)
  • Figure 6. Global Recombinant Vaccines: by Distribution Channel USD Million (2015-2020)
  • Figure 7. South America Recombinant Vaccines Share (%), by Country
  • Figure 8. Asia Pacific Recombinant Vaccines Share (%), by Country
  • Figure 9. Europe Recombinant Vaccines Share (%), by Country
  • Figure 10. MEA Recombinant Vaccines Share (%), by Country
  • Figure 11. North America Recombinant Vaccines Share (%), by Country
  • Figure 12. Global Recombinant Vaccines share by Players 2020 (%)
  • Figure 13. Global Recombinant Vaccines share by Players (Top 3) 2020(%)
  • Figure 14. Global Recombinant Vaccines share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Merck & Co., Inc (United States) Revenue, Net Income and Gross profit
  • Figure 17. Merck & Co., Inc (United States) Revenue: by Geography 2020
  • Figure 18. Green Cross Corporation (South Korea) Revenue, Net Income and Gross profit
  • Figure 19. Green Cross Corporation (South Korea) Revenue: by Geography 2020
  • Figure 20. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 22. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 24. Sanofi S A. (France) Revenue, Net Income and Gross profit
  • Figure 25. Sanofi S A. (France) Revenue: by Geography 2020
  • Figure 26. Protein Science Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 27. Protein Science Corporation (United States) Revenue: by Geography 2020
  • Figure 28. GlaxoSmithKline Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. GlaxoSmithKline Plc. (United Kingdom) Revenue: by Geography 2020
  • Figure 30. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 32. Bharat Biotech (India) Revenue, Net Income and Gross profit
  • Figure 33. Bharat Biotech (India) Revenue: by Geography 2020
  • Figure 34. Global Recombinant Vaccines: by Type USD Million (2021-2026)
  • Figure 35. Global Recombinant Vaccines: by Application USD Million (2021-2026)
  • Figure 36. Global Recombinant Vaccines: by Distribution Channel USD Million (2021-2026)
  • Figure 37. South America Recombinant Vaccines Share (%), by Country
  • Figure 38. Asia Pacific Recombinant Vaccines Share (%), by Country
  • Figure 39. Europe Recombinant Vaccines Share (%), by Country
  • Figure 40. MEA Recombinant Vaccines Share (%), by Country
  • Figure 41. North America Recombinant Vaccines Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Merck & Co., Inc (United States)
  • Green Cross Corporation (South Korea)
  • Pfizer Inc. (United States)
  • Bayer AG (Germany)
  • Sanofi S A. (France)
  • Protein Science Corporation (United States)
  • GlaxoSmithKline Plc. (United Kingdom)
  • Novartis AG (Switzerland)
  • Bharat Biotech (India)
Select User Access Type

Key Highlights of Report


Sep 2021 235 Pages 60 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Recombinant Vaccines Market Quantitative research analysis
Global Recombinant Vaccines Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Recombinant Vaccines market is expected to see a CAGR of 6.1% during projected year 2020 to 2026.
Top performing companies in the Global Recombinant Vaccines market are Merck & Co., Inc (United States), Green Cross Corporation (South Korea), Pfizer Inc. (United States), Bayer AG (Germany), Sanofi S A. (France), Protein Science Corporation (United States), GlaxoSmithKline Plc. (United Kingdom), Novartis AG (Switzerland) and Bharat Biotech (India), to name a few.
North America is dominating the Recombinant Vaccines Market.

Know More About Global Recombinant Vaccines Market Report?

Have a Query? Click Here

Other Related Reports

Serotonin Suppliment Comprehensive Study by Type (Tablets, Capsules, Liquid and Sprays, Others), Application (Depression Treatment, Anxiety Treatment, Others), Sales Channel (Over the Counter (OTC), ...
$ 3450
Revlimid Drug Comprehensive Study by Application (Hospital, Drugs Store, Other), Dosage (10mg, 25mg, Other) Players and Region - Global Market Outlook to 2026
$ 3500
Prescription Drugs Comprehensive Study by Type (Opinoids, Stimulants, Depressants), Application (Hospital, Clinic, Other), End users (Adults, Children), Drug type (Brand Drugs, Generic Drug), Distrib...
$ 3350
Rheumatoid Arthritis Drug Comprehensive Study by Route of Administration (Oral, Parenteral), End-users (Hospitals, Clinics, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharma...
$ 3750
Metabolic Disorders Drugs Comprehensive Study by Type (Glycogen Metabolism Disease Drug, Lipid Metabolism Disease Drug, Amino Acid Metabolism Drug), Application (Hospital, Retail Pharmacy), Route of ...
$ 3350
Psoriasis Drug Comprehensive Study by Type (Biologic Drugs, Small Molecule Systemic Drugs, Tropical Therapies), Application (Packaging, Automotive, Building and Construction), Route of Administration...
$ 3450